Siltuximab ( DrugBank: Siltuximab )

2 diseases

ID	Disease name (Link within this page)	Number of trials
28	Systemic amyloidosis	1
331	Idiopathic multicentric castleman disease	7

28. Systemic amyloidosis

Clinical trials : 267 / Drugs : 241 - (DrugBank : 77) / Drug target genes : 68 - Drug target pathways : 180

diseases per page:

Showing 1 to 1 of 1 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03315026 (ClinicalTrials.gov)	December 14, 2017	13/10/2017	Siltuximabto Decrease Symptom Burden After Autologous Stem Cell Transplantation for Patients With Mu ...	Phase II Study of Interleukin 6 Blockade With Siltuximabto Decrease Symptom Burden in Patients Age 6 ...	Multiple Myeloma;AL Amyloidosis	Drug: Siltuximab;Behavioral: The M.D. Anderson Symptom Inventory (MDASI)	Memorial Sloan Kettering Cancer Center	Janssen Scientific Affairs, LLC	Active, not recruiting	60 Years	75 Years	All	30	Phase 2	United States

First Previous1Next Last

331. Idiopathic multicentric castleman disease

Clinical trials : 33 / Drugs : 41 - (DrugBank : 21) / Drug target genes : 22 - Drug target pathways : 123

diseases per page:

Showing 1 to 7 of 7 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04838860 (ClinicalTrials.gov)	March 31, 2021	25/2/2021	Siltuximab In Siltuximab-RElapsed/REfractory Multicentric CAstleman Disease	A Phase 2 Study of Intrapatient SiltuximabDose Escalation in Patients With Idiopathic Multicentric C ...	Idiopathic Multicentric Castleman's Disease	Drug: Siltuximab	EusaPharma (UK) Limited	NULL	Terminated	12 Years	N/A	All	22	Phase 2	United States
2	EUCTR2010-022837-27-GB (EUCTR)	15/02/2013	01/08/2012	A Study to Evaluate the Safety of Long-term Treatment with Siltuximabin Patients with Multicentric C ...	An Open-label, Multicenter Study to Evaluate the Safety of Long-term Treatment with Siltuximabin Sub ...	Multicentric Castleman's Disease MedDRA version: 14.1;Level: PT;Classification code 10050251;Term: C ...	Product Name: CNTO328 Product Code: CNTO328 Other descriptive name: SILTUXIMAB	Janssen-Cilag International N.V.	NULL	Not Recruiting			Female: yes Male: yes	75	Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): yes Therapeutic confirmatory - ( ...	United States;Hong Kong;Taiwan;Spain;Israel;United Kingdom;Egypt;France;Canada;Belgium;Brazil;Singap ...
3	EUCTR2010-022837-27-BE (EUCTR)	17/12/2012	23/07/2012	A Study to Evaluate the Safety of Long-term Treatment with Siltuximabin Patients with Multicentric C ...	An Open-label, Multicenter Study to Evaluate the Safety of Long-term Treatment with Siltuximabin Sub ...	Multicentric Castleman's Disease MedDRA version: 17.0;Level: PT;Classification code 10050251;Term: C ...	Product Name: CNTO328 Product Code: CNTO328 Other descriptive name: SILTUXIMAB	Janssen-Cilag International N.V.	NULL	Not Recruiting			Female: yes Male: yes	75	Phase 2	United States;Taiwan;Hong Kong;Spain;Israel;United Kingdom;Egypt;France;Canada;Belgium;Brazil;Singap ...
4	EUCTR2010-022837-27-ES (EUCTR)	29/11/2012	26/09/2012	A Study to Evaluate the Safety of Long-term Treatment with Siltuximabin Patients with Multicentric C ...	An Open-label, Multicenter Study to Evaluate the Safety of Long-term Treatment with Siltuximabin Sub ...	Multicentric Castleman's Disease MedDRA version: 15.0;Level: PT;Classification code 10050251;Term: C ...	Product Name: CNTO328 Product Code: CNTO328 INN or Proposed INN: NA Other descriptive name: SILTUXIMAB	Janssen-Cilag International N.V.	NULL	Not Recruiting			Female: yes Male: yes	80	Phase 2	United States;Hong Kong;Taiwan;Spain;Israel;United Kingdom;Egypt;France;Canada;Belgium;Brazil;Singap ...
5	EUCTR2010-022837-27-DE (EUCTR)	21/11/2012	19/09/2012	A Study to Evaluate the Safety of Long-term Treatment with Siltuximabin Patients with Multicentric C ...	An Open-label, Multicenter Study to Evaluate the Safety of Long-term Treatment with Siltuximabin Sub ...	Multicentric Castleman's Disease MedDRA version: 17.0;Level: PT;Classification code 10050251;Term: C ...	Product Name: CNTO328 Product Code: CNTO328 Other descriptive name: SILTUXIMAB	Janssen-Cilag International N.V.	NULL	Not Recruiting			Female: yes Male: yes	75	Phase 2	United States;Taiwan;Hong Kong;Spain;Israel;United Kingdom;Egypt;France;Canada;Belgium;Brazil;Singap ...
6	NCT01400503 (ClinicalTrials.gov)	April 1, 2011	21/4/2011	A Study to Evaluate the Safety of Long-term Treatment With Siltuximabin Patients With Multicentric C ...	An Open-label, Multicenter Study to Evaluate the Safety of Long-term Treatment With Siltuximabin Sub ...	Multicentric Castleman's Disease	Drug: Siltuximab	Janssen Research & Development, LLC	NULL	Completed	18 Years	N/A	All	60	Phase 2	United States;Belgium;Brazil;Canada;China;Egypt;France;Germany;Hong Kong;Israel;Korea, Republic of;N ...
7	NCT01024036 (ClinicalTrials.gov)	March 18, 2010	30/11/2009	A Study to Evaluate the Efficacy and Safety of CNTO328 Plus Best Supportive Care in Multicentric Cas ...	A Randomized, Double Blind, Placebo Controlled Study to Assess the Efficacy and Safety of CNTO 328 ( ...	Multicentric Castleman's Disease	Drug: Siltuximab;Drug: Placebo;Drug: Best Supportive Care (BSC)	Janssen Research & Development, LLC	NULL	Completed	18 Years	N/A	All	79	Phase 2	United States;Australia;Belgium;Brazil;Canada;China;Egypt;France;Germany;Hong Kong;Hungary;India;Isr ...

First Previous1Next Last